The Filings Report

Elevance Health, Inc.

ELVNYSECIK 1156039Healthcare / Healthcare Plansfiscal year ends December74 quarters since 2008

Revenue, Q3 FY2026
$51.4B
+1.4% on Q3 FY2025
Net income
$1.4B
+14.8% on Q3 FY2025
Free cash flow
$1.0B
+29.0% on Q3 FY2025
Diluted EPS
$6.27
+17.9% on Q3 FY2025
Revenue, TTM
$201.8B
trailing four quarters
Net margin, TTM
2.5%
net income $5.1B
Free cash flow, TTM
$6.5B
$7.6B less $1.1B capex
Cash and equivalents
$10.3B
long-term debt $30.4B, Sep 30, 2026
Shares, 12-month change
−2.8%
216M shares, Sep 30, 2026
Buybacks, TTM
$2.2B
2.4% of market value
Dividends, TTM
$1.5B
1.6% of market value
Market value
$90.8B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 21, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Elevance Health, Inc. reported revenue of $51.4B, +1.4% on Q3 FY2025, and net income of $1.4B (+14.8%). Operating margin was 2.5%. Free cash flow, operating cash flow less capital expenditures, was $1.0B ($1.3B less $267M). Diluted earnings per share were $6.27.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 21, 2026.

Revenue and net incomeRevenueNet income
$0$20B$40B$60BQ4'22, Revenue: $39.9BQ4'22, Net income: $865MQ4'22Q1'23, Revenue: $42.2BQ1'23, Net income: $2.0BQ1'23Q2'23, Revenue: $43.7BQ2'23, Net income: $1.9BQ2'23Q3'23, Revenue: $42.8BQ3'23, Net income: $1.3BQ3'23Q4'23, Revenue: $42.6BQ4'23, Net income: $856MQ4'23Q1'24, Revenue: $42.6BQ1'24, Net income: $2.2BQ1'24Q2'24, Revenue: $43.9BQ2'24, Net income: $2.3BQ2'24Q3'24, Revenue: $45.1BQ3'24, Net income: $1.0BQ3'24Q4'24, Revenue: $45.4BQ4'24, Net income: $418MQ4'24Q1'25, Revenue: $48.9BQ1'25, Net income: $2.2BQ1'25Q2'25, Revenue: $49.8BQ2'25, Net income: $1.7BQ2'25Q3'25, Revenue: $50.7BQ3'25, Net income: $1.2BQ3'25Q4'25, Revenue: $49.7BQ4'25, Net income: $547MQ4'25Q1'26, Revenue: $50.2BQ1'26, Net income: $1.8BQ1'26Q2'26, Revenue: $50.5BQ2'26, Net income: $1.5BQ2'26Q3'26, Revenue: $51.4BQ3'26, Net income: $1.4BQ3'26$0$20B$40B$60BQ4'22, Revenue: $39.9BQ4'22, Net income: $865MQ1'23, Revenue: $42.2BQ1'23, Net income: $2.0BQ1'23Q2'23, Revenue: $43.7BQ2'23, Net income: $1.9BQ3'23, Revenue: $42.8BQ3'23, Net income: $1.3BQ3'23Q4'23, Revenue: $42.6BQ4'23, Net income: $856MQ1'24, Revenue: $42.6BQ1'24, Net income: $2.2BQ1'24Q2'24, Revenue: $43.9BQ2'24, Net income: $2.3BQ3'24, Revenue: $45.1BQ3'24, Net income: $1.0BQ3'24Q4'24, Revenue: $45.4BQ4'24, Net income: $418MQ1'25, Revenue: $48.9BQ1'25, Net income: $2.2BQ1'25Q2'25, Revenue: $49.8BQ2'25, Net income: $1.7BQ3'25, Revenue: $50.7BQ3'25, Net income: $1.2BQ3'25Q4'25, Revenue: $49.7BQ4'25, Net income: $547MQ1'26, Revenue: $50.2BQ1'26, Net income: $1.8BQ1'26Q2'26, Revenue: $50.5BQ2'26, Net income: $1.5BQ3'26, Revenue: $51.4BQ3'26, Net income: $1.4BQ3'26

Net income losses drawn in red.

Free cash flow
−$5B−$3B$0$3B$5B$8BQ4'22, Free cash flow: −$1.8BQ4'22Q1'23, Free cash flow: $6.2BQ1'23Q2'23, Free cash flow: $1.6BQ2'23Q3'23, Free cash flow: $2.3BQ3'23Q4'23, Free cash flow: −$3.3BQ4'23Q1'24, Free cash flow: $1.7BQ1'24Q2'24, Free cash flow: $124MQ2'24Q3'24, Free cash flow: $2.3BQ3'24Q4'24, Free cash flow: $384MQ4'24Q1'25, Free cash flow: $821MQ1'25Q2'25, Free cash flow: $1.8BQ2'25Q3'25, Free cash flow: $775MQ3'25Q4'25, Free cash flow: −$209MQ4'25Q1'26, Free cash flow: $4.1BQ1'26Q2'26, Free cash flow: $1.6BQ2'26Q3'26, Free cash flow: $1.0BQ3'26−$5B−$3B$0$3B$5B$8BQ4'22, Free cash flow: −$1.8BQ1'23, Free cash flow: $6.2BQ1'23Q2'23, Free cash flow: $1.6BQ3'23, Free cash flow: $2.3BQ3'23Q4'23, Free cash flow: −$3.3BQ1'24, Free cash flow: $1.7BQ1'24Q2'24, Free cash flow: $124MQ3'24, Free cash flow: $2.3BQ3'24Q4'24, Free cash flow: $384MQ1'25, Free cash flow: $821MQ1'25Q2'25, Free cash flow: $1.8BQ3'25, Free cash flow: $775MQ3'25Q4'25, Free cash flow: −$209MQ1'26, Free cash flow: $4.1BQ1'26Q2'26, Free cash flow: $1.6BQ3'26, Free cash flow: $1.0BQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$10B$20B$30B$40BQ4'22, Cash and equivalents: $7.4BQ4'22, Long-term debt: $22.3BQ4'22Q1'23, Cash and equivalents: $10.1BQ1'23, Long-term debt: $25.2BQ1'23Q2'23, Cash and equivalents: $10.0BQ2'23, Long-term debt: $24.9BQ2'23Q3'23, Cash and equivalents: $10.9BQ3'23, Long-term debt: $24.0BQ3'23Q4'23, Cash and equivalents: $6.5BQ4'23, Long-term debt: $23.2BQ4'23Q1'24, Cash and equivalents: $6.2BQ1'24, Long-term debt: $22.0BQ1'24Q2'24, Cash and equivalents: $6.5BQ2'24, Long-term debt: $24.6BQ2'24Q3'24, Cash and equivalents: $7.9BQ3'24, Long-term debt: $24.7BQ3'24Q4'24, Cash and equivalents: $8.3BQ4'24, Long-term debt: $29.2BQ4'24Q1'25, Cash and equivalents: $7.5BQ1'25, Long-term debt: $28.1BQ1'25Q2'25, Cash and equivalents: $8.6BQ2'25, Long-term debt: $28.2BQ2'25Q3'25, Cash and equivalents: $8.7BQ3'25, Long-term debt: $31.2BQ3'25Q4'25, Cash and equivalents: $9.5BQ4'25, Long-term debt: $30.8BQ4'25Q1'26, Cash and equivalents: $9.7BQ1'26, Long-term debt: $30.8BQ1'26Q2'26, Cash and equivalents: $10.2BQ2'26, Long-term debt: $30.7BQ2'26Q3'26, Cash and equivalents: $10.3BQ3'26, Long-term debt: $30.4BQ3'26$0$10B$20B$30B$40BQ4'22, Cash and equivalents: $7.4BQ4'22, Long-term debt: $22.3BQ1'23, Cash and equivalents: $10.1BQ1'23, Long-term debt: $25.2BQ1'23Q2'23, Cash and equivalents: $10.0BQ2'23, Long-term debt: $24.9BQ3'23, Cash and equivalents: $10.9BQ3'23, Long-term debt: $24.0BQ3'23Q4'23, Cash and equivalents: $6.5BQ4'23, Long-term debt: $23.2BQ1'24, Cash and equivalents: $6.2BQ1'24, Long-term debt: $22.0BQ1'24Q2'24, Cash and equivalents: $6.5BQ2'24, Long-term debt: $24.6BQ3'24, Cash and equivalents: $7.9BQ3'24, Long-term debt: $24.7BQ3'24Q4'24, Cash and equivalents: $8.3BQ4'24, Long-term debt: $29.2BQ1'25, Cash and equivalents: $7.5BQ1'25, Long-term debt: $28.1BQ1'25Q2'25, Cash and equivalents: $8.6BQ2'25, Long-term debt: $28.2BQ3'25, Cash and equivalents: $8.7BQ3'25, Long-term debt: $31.2BQ3'25Q4'25, Cash and equivalents: $9.5BQ4'25, Long-term debt: $30.8BQ1'26, Cash and equivalents: $9.7BQ1'26, Long-term debt: $30.8BQ1'26Q2'26, Cash and equivalents: $10.2BQ2'26, Long-term debt: $30.7BQ3'26, Cash and equivalents: $10.3BQ3'26, Long-term debt: $30.4BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 21, 2026.

Elevance Health, Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 21, 2026Q2 FY2026ended Jun 30, 2026filed Jul 15, 2026Q1 FY2026ended Mar 31, 2026filed Apr 22, 2026Q4 FY2025ended Dec 31, 2025filed Feb 6, 2026Q3 FY2025ended Sep 30, 2025filed Oct 21, 2025Q2 FY2025ended Jun 30, 2025filed Jul 17, 2025Q1 FY2025ended Mar 31, 2025filed Apr 22, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue51,42950,47450,18149,74750,71149,77648,89145,442+1.4%
Cost of revenue5,6405,4925,4635,5225,3805,2934,9836,012+4.8%
Gross profit—————————
Research and development—————————
Selling, general and administrative5,7525,5476,3305,4155,2724,9975,3004,804+9.1%
Operating income1,2691,7632,0863091,2952,4253,170673−2.0%
Other income (expense)—————————
Pretax income1,7941,9372,3042151,4062,2922,797606+27.6%
Income tax451483544(331)219548613193+105.9%
Net income1,3651,4631,7645471,1891,7432,183418+14.8%
Diluted EPS ($)6.276.718.00—5.327.729.61—+17.9%
Diluted shares (millions)218218220—224226227——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 21, 2026.

Elevance Health, Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 21, 2026Q2 FY2026ended Jun 30, 2026filed Jul 15, 2026Q1 FY2026ended Mar 31, 2026filed Apr 22, 2026Q4 FY2025ended Dec 31, 2025filed Feb 6, 2026Q3 FY2025ended Sep 30, 2025filed Oct 21, 2025Q2 FY2025ended Jun 30, 2025filed Jul 17, 2025Q1 FY2025ended Mar 31, 2025filed Apr 22, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents10,34810,2329,6579,4918,7138,5607,5008,288+18.8%
Short-term investments25,34725,71925,90525,88426,28325,29825,43725,201−3.6%
Total current assets68,52467,18467,03263,00163,77863,32461,12158,942+7.4%
Total assets127,801126,438125,827121,494122,749121,938119,717116,889+4.1%
Total current liabilities46,66244,25445,30941,03540,87843,83442,69840,581+14.1%
Long-term debt30,38230,66930,76830,79731,17328,17828,11029,218−2.5%
Total liabilities83,00781,41681,78577,46878,66778,08777,09775,463+5.5%
Stockholders’ equity44,68144,88343,90243,88243,95343,72242,50341,315+1.7%
Shares outstanding (millions)216217217221222225226227—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 21, 2026.

Elevance Health, Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 21, 2026Q2 FY2026ended Jun 30, 2026filed Jul 15, 2026Q1 FY2026ended Mar 31, 2026filed Apr 22, 2026Q4 FY2025ended Dec 31, 2025filed Feb 6, 2026Q3 FY2025ended Sep 30, 2025filed Oct 21, 2025Q2 FY2025ended Jun 30, 2025filed Jul 17, 2025Q1 FY2025ended Mar 31, 2025filed Apr 22, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow1,2671,9134,332841,1352,0541,017706+11.6%
Capital expenditures267287235293360267196322−25.8%
Free cash flow (CFO − capex)1,0001,6264,097(209)7751,787821384+29.0%
Depreciation and amortization363366354406387380373withheld−6.2%
Share repurchases3302341,1244718763788801,811−62.3%
Dividends paid373373376377381385386373−2.1%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 6, 2026.

Income statement

Elevance Health, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 6, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 15, 2023FY2021ended Dec 31, 2021filed Feb 16, 2022FY2020ended Dec 31, 2020filed Feb 18, 2021FY2019ended Dec 31, 2019filed Feb 19, 2020FY2018ended Dec 31, 2018filed Feb 20, 2019FY2017ended Dec 31, 2017filed Feb 21, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 22, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed Feb 18, 2010FY2008ended Dec 31, 2008filed Jul 29, 2009FY2007ended Dec 31, 2007filed Jul 29, 2009
Revenue199,125177,011171,340156,595138,639121,867104,21392,10590,04084,86379,15773,87471,02461,49760,71158,69964,94061,25161,168
Cost of revenue21,17819,75017,29313,03510,8958,9531,99200——————————
Gross profit———————————————————
Research and development———————————————————
Selling, general and administrative20,98420,02520,08717,70015,91817,45013,36414,02012,65012,55912,53511,7489,9538,6818,4368,7339,0198,4978,702
Operating income7,1997,8628,4998,2837,5596,3605,9995,4264,1754,8014,7534,4184,0013,6203,7824,0784,1794,348—
Other income (expense)———————————————————
Pretax income6,7107,9047,7157,6007,9956,2385,9855,0683,9644,5554,6314,3683,8403,8583,9584,3547,4033,1225,258
Income tax1,0491,9331,7241,7121,8461,6661,1781,3181212,0852,0711,8081,2061,2071,3111,4672,6576321,913
Net income5,6625,9805,9875,8946,1584,5724,8073,7503,8432,4702,5602,5702,4902,6562,6472,8874,7462,4913,345
Diluted EPS ($)25.2125.6825.2224.2824.9517.9818.4714.1914.359.219.388.998.208.187.256.949.884.765.56
Diluted shares (millions)225233237243247254260264268268273286304325365416481523—

Balance sheet

Elevance Health, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 6, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 15, 2023FY2021ended Dec 31, 2021filed Feb 16, 2022FY2020ended Dec 31, 2020filed Feb 18, 2021FY2019ended Dec 31, 2019filed Feb 19, 2020FY2018ended Dec 31, 2018filed Feb 20, 2019FY2017ended Dec 31, 2017filed Feb 21, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 22, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed Feb 18, 2010FY2008ended Dec 31, 2008filed Jul 29, 2009FY2007ended Dec 31, 2007filed Jul 29, 2009
Cash and equivalents9,4918,2886,5267,3874,8805,7414,9373,9343,6094,0752,1132,1521,5822,4752,2021,7894,8162,1842,768
Short-term investments25,88425,20129,61425,95226,26723,43319,67616,69217,37717,16316,92017,46717,03816,91315,91316,07015,6971,565—
Total current assets63,00158,94260,02955,61751,12245,75139,03334,32136,26334,31530,86231,94829,74629,34827,09726,14128,07112,130—
Total assets121,494116,889108,928102,75597,45686,61577,45371,57170,54065,08361,71861,67659,57558,95552,16350,16752,12548,403—
Total current liabilities41,03540,58141,79139,69634,88529,45323,53221,96523,35621,29419,09318,75316,35215,99515,89914,01014,67415,020—
Long-term debt30,79729,21823,24622,34921,15719,33517,78717,21717,38214,35915,32514,02013,57414,1718,4668,1488,3387,834—
Total liabilities77,46875,46369,52366,42561,29353,41645,72543,03044,03739,98338,67437,42534,80935,15328,87526,35427,26226,972—
Stockholders’ equity43,88241,31539,30636,24336,09533,19931,72828,54126,50325,10123,04524,25124,76523,80323,28823,81324,86321,43222,990
Shares outstanding (millions)221227233237241245252257256264261267282300335376444——

Cash flow statement

Elevance Health, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 6, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 15, 2023FY2021ended Dec 31, 2021filed Feb 16, 2022FY2020ended Dec 31, 2020filed Feb 18, 2021FY2019ended Dec 31, 2019filed Feb 19, 2020FY2018ended Dec 31, 2018filed Feb 20, 2019FY2017ended Dec 31, 2017filed Feb 21, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 22, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed Feb 18, 2010FY2008ended Dec 31, 2008filed Jul 29, 2009FY2007ended Dec 31, 2007filed Jul 29, 2009
Operating cash flow4,2905,8088,0618,3998,36410,6886,0613,8274,1853,2704,2123,3693,0522,7453,3741,4173,0392,5354,345
Capital expenditures1,1161,2561,2961,1521,0871,0211,0771,208791584638715647545520451378346322
Free cash flow (CFO − capex)3,1744,5526,7657,2477,2779,6674,9842,6193,3942,6863,5742,6552,4062,2002,8559652,6612,1904,023
Depreciation and amortization1,5461,3931,7451,6751,3021,1541,1331,132———————————
Share repurchases2,6052,9002,6762,3161,9002,7001,7011,6851,99801,5162,9991,6202,4973,0404,3602,6383,2766,151
Dividends paid1,5291,5081,3951,2291,1049548187767056846574814483673580———

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$5M
13 sales by 1 insider; officers and directors $5M
Bought, twelve months
$2M
4 purchases by 3 insiders; officers and directors $2M
Sold, twelve months
$6M
18 sales by 5 insiders; officers and directors $6M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale400$434.00$174K30,103Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale321$435.25$140K29,782Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale1,660$436.20$724K28,122Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale560$437.07$245K27,562Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale240$438.22$105K27,322Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale1,160$439.25$510K26,162Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale1,720$440.44$758K24,442Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale2,343$441.34$1M22,099Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale480$442.61$212K21,619Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale440$443.81$195K21,179Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale160$444.85$71K21,019Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale827$446.05$369K20,192Oct 23, 2026
Oct 22, 2026Kaye MarkEVP & CFOopen-market sale273$447.19$122K19,919Oct 23, 2026
Oct 2, 2026Kaye MarkEVP & CFOtax withholding4,161$386.43$2M27,876Oct 6, 2026
Oct 2, 2026Kaye MarkEVP & CFOaward2,627$0.00—30,503Oct 6, 2026
Sep 3, 2026Wessling Erin MEVP & Chief Legal Officertax withholding255$414.78$106K7,230Sep 4, 2026
Sep 2, 2026Wessling Erin MEVP & Chief Legal Officertax withholding94$405.84$38K7,485Sep 4, 2026
Sep 2, 2026Craig Ryan REVP & Chief HR Officertax withholding144$405.84$58K6,530Sep 4, 2026
Jul 17, 2026Peru Ramiro GDirectoropen-market buy1,000$366.05$366K10,908Jul 17, 2026
Jul 17, 2026Boudreaux GailPresident and CEO, Directoropen-market buy680$366.41$249K169,931Jul 17, 2026
Jul 17, 2026Boudreaux GailPresident and CEO, Directoropen-market buy2,045$368.25$753K171,976Jul 17, 2026
Jun 12, 2026Penczek Ronald WCAO & Controlleropen-market sale369$403.16$149K3,740Jun 15, 2026
Jun 11, 2026Dixon Robert L JRDirectoropen-market sale151$401.77$61K10,734Jun 12, 2026
May 19, 2026Penczek Ronald WCAO & Controlleroption exercise654$271.27$177K4,763May 20, 2026
May 19, 2026Penczek Ronald WCAO & Controlleroption exercise877$311.48$273K5,640May 20, 2026

Full insider history for Elevance Health, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held ELV in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded ELV by quarter.

FundManagerQuarterValueSharesWeightMove
Baupost GroupSeth KlarmanQ2 2026$493M1M9.11%held
Baron Capital GroupRon BaronQ2 2026$2M5,0000.00%new

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
ELEVANCE HEALTH, INC., CIK 1156039 on EDGAR
Extract generated
October 22, 2026
Withheld
2 line-years whose four quarters do not sum to the filed year: depreciation amortization FY2023, depreciation amortization FY2024
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2017
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): not filed
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAmortizationAndAccretionNet, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated October 22, 2026.

JSON file
/data/financials/ELV.json